BRIEF-Oncosec Announces Clinical Data Of The Keynote-695 Trial Assessing Tavo-Ep In Combination With Keytruda (Pembrolizumab)

Reuters

Apr 03, 2023

April 3 (Reuters) - OncoSec Medical Inc :

* ONCOSEC ANNOUNCES CLINICAL DATA OF THE KEYNOTE-695 TRIAL ASSESSING TAVO™-EP IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH ADVANCED MELANOMA REFRACTORY TO ANTI-PD-1 TREATMENT

* ONCOSEC MEDICAL INC - PRIMARY ENDPOINT OF ORR PER RECIST V1.1 ASSESSED BY BLINDED INDEPENDENT CENTRAL REVIEW (BICR) WAS NOT MET IN STUDY

* ONCOSEC MEDICAL INC - COMPANY PLANS TO PURSUE TAVO™-EP IN COMBINATION WITH ANTI-PD-1 THERAPY IN NEOADJUVANT MELANOMA SETTING

* ONCOSEC MEDICAL - MEETING WITH FDA TO DISCUSS PHASE 2 RANDOMIZED TRIAL DESIGN, DEVELOPMENT PLANS IN MELANOMA NEOADJUVANT SETTING IS SCHEDULED IN MAY

Source text for Eikon: Further company coverage:

((reuters.briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2324350869"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2324350869\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2324350869?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-04-03 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2324350869","market":"us","top_or_hot":-1,"title":"BRIEF-Oncosec Announces Clinical Data Of The Keynote-695 Trial Assessing Tavo-Ep In Combination With Keytruda (Pembrolizumab)","media":"Reuters","content":"<html><body><p>April 3 (Reuters) - OncoSec Medical Inc   :</p><p>   * ONCOSEC ANNOUNCES CLINICAL DATA OF THE KEYNOTE-695 TRIAL ASSESSING TAVO™-EP IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH ADVANCED MELANOMA REFRACTORY TO ANTI-PD-1 TREATMENT</p><p>   * ONCOSEC MEDICAL INC - PRIMARY ENDPOINT OF ORR PER RECIST V1.1 ASSESSED BY BLINDED INDEPENDENT CENTRAL REVIEW (BICR) WAS NOT MET IN STUDY</p><p>   * ONCOSEC MEDICAL INC - COMPANY PLANS TO PURSUE TAVO™-EP IN COMBINATION WITH ANTI-PD-1 THERAPY IN NEOADJUVANT MELANOMA SETTING</p><p>   * ONCOSEC MEDICAL - MEETING WITH FDA TO DISCUSS PHASE 2 RANDOMIZED TRIAL DESIGN,  DEVELOPMENT PLANS IN MELANOMA NEOADJUVANT SETTING IS SCHEDULED IN MAY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Oncosec Announces Clinical Data Of The Keynote-695 Trial Assessing Tavo-Ep In Combination With Keytruda (Pembrolizumab)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Oncosec Announces Clinical Data Of The Keynote-695 Trial Assessing Tavo-Ep In Combination With Keytruda (Pembrolizumab)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2023-04-03 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>April 3 (Reuters) - OncoSec Medical Inc   :</p><p>   * ONCOSEC ANNOUNCES CLINICAL DATA OF THE KEYNOTE-695 TRIAL ASSESSING TAVO™-EP IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH ADVANCED MELANOMA REFRACTORY TO ANTI-PD-1 TREATMENT</p><p>   * ONCOSEC MEDICAL INC - PRIMARY ENDPOINT OF ORR PER RECIST V1.1 ASSESSED BY BLINDED INDEPENDENT CENTRAL REVIEW (BICR) WAS NOT MET IN STUDY</p><p>   * ONCOSEC MEDICAL INC - COMPANY PLANS TO PURSUE TAVO™-EP IN COMBINATION WITH ANTI-PD-1 THERAPY IN NEOADJUVANT MELANOMA SETTING</p><p>   * ONCOSEC MEDICAL - MEETING WITH FDA TO DISCUSS PHASE 2 RANDOMIZED TRIAL DESIGN,  DEVELOPMENT PLANS IN MELANOMA NEOADJUVANT SETTING IS SCHEDULED IN MAY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CGEM","symbol_name":"Cullinan Therapeutics","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2324350869","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2324350869","pubTimestamp":1680521496,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 3 (Reuters) - OncoSec Medical Inc   :   * ONCOSEC ANNOUNCES CLINICAL DATA OF THE KEYNOTE-695 T","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CGEM":"Cullinan Therapeutics","BK4534":"瑞士信贷持仓","ONTF":"ON24, Inc.","BK4139":"生物科技","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0861579265.USD":"联博低波幅策略股票基金A","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0122379950.USD":"贝莱德世界健康科学A2","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK4082":"医疗保健设备","SG9999014559.SGD":"United Income Focus Trust Dis SGD","MRK":"默沙东","BK4559":"巴菲特持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4550":"红杉资本持仓","SG9999001176.USD":"United Global Healthcare Acc USD","LHDX":"Lucira Health, Inc.","BK4588":"碎股","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","SANA":"Sana Biotechnology, Inc.","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","BK4007":"制药","LABP":"Landos Biopharma, Inc.","SG9999002232.USD":"Allianz Global High Payout USD","BK4196":"保健护理服务","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","BK4585":"ETF&股票定投概念","BK4023":"应用软件","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC"},"translate_title":"简介——Oncosec公布Keynote-695试验的临床数据，该试验评估Tavo-Ep与Keytruda（彭布罗利珠单抗）的联合应用","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGEM":0.83,"LHDX":0.83,"ONTF":0.9,"MRK":1,"ONCS":0.9,"LABP":0.83,"SANA":0.83},"content_text":"April 3 (Reuters) - OncoSec Medical Inc   :   * ONCOSEC ANNOUNCES CLINICAL DATA OF THE KEYNOTE-695 TRIAL ASSESSING TAVO™-EP IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH ADVANCED MELANOMA REFRACTORY TO ANTI-PD-1 TREATMENT   * ONCOSEC MEDICAL INC - PRIMARY ENDPOINT OF ORR PER RECIST V1.1 ASSESSED BY BLINDED INDEPENDENT CENTRAL REVIEW (BICR) WAS NOT MET IN STUDY   * ONCOSEC MEDICAL INC - COMPANY PLANS TO PURSUE TAVO™-EP IN COMBINATION WITH ANTI-PD-1 THERAPY IN NEOADJUVANT MELANOMA SETTING   * ONCOSEC MEDICAL - MEETING WITH FDA TO DISCUSS PHASE 2 RANDOMIZED TRIAL DESIGN,  DEVELOPMENT PLANS IN MELANOMA NEOADJUVANT SETTING IS SCHEDULED IN MAYSource text for Eikon:    Further company coverage:    ((reuters.briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}